Skip to main content
. Author manuscript; available in PMC: 2010 May 4.
Published in final edited form as: Mol Ther. 2008 Aug 19;16(10):1695–1702. doi: 10.1038/mt.2008.168

Figure 2. Pretreatment of brain with AAV-CBA-hIFN-b provides 100% survival against glioma challenge.

Figure 2

Kaplan–Meier survival analysis of mice pretreated as in (Figure 1a) and later implanted with (a) 5 × 105 U87fluc-mCherry cells, or (b) 105 U87fluc-mCherry-EGFRvIII cells. Solid line indicates AAV-CBA-IFN-β-treated mice, while dashed line indicates AAV-empty vector–treated mice (six mice per group). AAV, adeno-associated virus; CBA, chicken β-actin; EGFRvIII, epidermal growth factor receptor variant III; hIFN-β, human interferon-β.

HHS Vulnerability Disclosure